Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Office of New Drugs director returns

Executive Summary

FDA Office of New Drugs Director John Jenkins returns to his position at the agency following a personal leave. OND Deputy Director Sandra Kweder served as acting director during Jenkins' absence. Kweder represented the office on the decision to request a "black box" warning on antidepressant labeling and testified on behalf of FDA at the Senate Finance Committee's hearing on the Vioxx withdrawal (1"The Pink Sheet" Oct. 18, 2004, p. 3). Jenkins represented OND on a Dec. 17 conference call on Celebrex safety data...

You may also be interested in...



Antidepressant “Black Box” Presents Barrier To DTC Advertising

FDA's proposed "black box" warning for all antidepressants would likely mean an end to television ads for the products

Independent Beauty Association Adds Global Supply-Chain Expertise; Cosmetics Appointments In Brief

The Honest Company’s new digital and strategy chief joins from Amazon.com where he led development of home security systems and contactless, in-garage delivery for more than 50m Amazon Key customers. More cosmetics people news, including new supply chain and sustainability leadership at the Independent Beauty Association.

A PDUFA First: Pre-Approval Inspection Notice Goal Will Be Created

Under new user fee agreement, sponsors will get at least 60-day notice when a pre-approval inspection is necessary; regulators and manufacturers hope increased communications will lead to more efficient reviews.

Topics

UsernamePublicRestriction

Register

PS045191

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel